LENZ Therapeutics Collaborates with Lotus Pharmaceutical to Commercialize LNZ100 in the Republic of Korea and Southeast Asia

Shots:

• LENZ has granted Lotus exclusive development, manufacturing, registration & marketing rights of LNZ100 to treat presbyopia in the Republic of Korea & certain Southeast Asian countries incl. Thailand, Philippines, Vietnam, Malaysia, Brunei, Indonesia & Singapore
• As per the deal, LENZ will obtain ~$125M in upfront, regulatory & commercial milestones, along with double-digit net sales-based tiered royalties
• In Oct 2024, the US FDA has accepted NDA of LNZ100 (QD), a preservative-free aceclidine eye drop for presbyopia, based on P-III (CLARITY) trial data, with no advisory committee meeting to be planned (PDUFA: Aug 8, 2025)

Ref: GlobeNewswire | Image: LENZ Therapeutics and Lotus Pharmaceutical

Related News:- Lotus Pharmaceutical and Formycon Enter into a Strategic Partnership to Commercialize FYB203/Ahzantive (Biosimilar, Eylea) in APAC

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click Here for Full Press Release